Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Operating Margin (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Operating Margin data on record, last reported at 405.3% in Q3 2025.

  • For Q3 2025, Operating Margin rose 20776.0% year-over-year to 405.3%; the TTM value through Sep 2025 reached 13.22%, up 71383.0%, while the annual FY2024 figure was 277.31%, 102990.0% up from the prior year.
  • Operating Margin reached 405.3% in Q3 2025 per STOK's latest filing, down from 197.58% in the prior quarter.
  • Across five years, Operating Margin topped out at 70.15% in Q1 2025 and bottomed at 1340.67% in Q2 2023.
  • Average Operating Margin over 4 years is 637.28%, with a median of 672.96% recorded in 2024.
  • Peak YoY movement for Operating Margin: tumbled -55958bps in 2023, then soared 99551bps in 2024.
  • A 4-year view of Operating Margin shows it stood at 831.58% in 2022, then decreased by -27bps to 1055.89% in 2023, then surged by 94bps to 60.38% in 2024, then tumbled by -571bps to 405.3% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 405.3% in Q3 2025, 197.58% in Q2 2025, and 70.15% in Q1 2025.